Søgeresultater - A Guilhem
- Showing 1 - 4 results of 4
-
1
-
2
-
3
Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients af A Guilhem, Anne‐Emmanuelle Fargeton, Anne-Claire Simon, P. Duffau, Jean‐Robert Harlé, Christian Lavigne, Marie‐France Carette, O Blétry, P. Kaminsky, V. Leguy, Nathalie Lerolle, Dominique Roux, M. Lambert, Thierry Chinet, Delphine Bonnet, Sophie Dupuis‐Girod, Sophie Rivière
Udgivet 2017Artigo -
4
The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome af Mathieu Blot, Jean‐Baptiste Bour, Jean‐Pierre Quenot, Abderrahmane Bourredjem, Maxime Nguyen, Julien Guy, Serge Monier, Marjolaine Georges, Audrey Large, Auguste Dargent, A Guilhem, S. Mouriès-Martin, Jérémy Barben, Bélaïd Bouhemad, Pierre‐Emmanuel Charles, P. Chavanet, Christine Binquet, Lionel Piroth, Pascal Andreu, François Aptel, Marie Labruyère, Sébastien Prin, Guillaume Beltramo, Philippe Bonniaud, P. Bielefeld, Hervé Devilliers, Bernard Bonnotte, Marielle Buisson, Alain Putot
Udgivet 2020Artigo
Søgeredskaber:
Relaterede emner
Medicine
Internal medicine
Disease
Immune system
Immunology
Telangiectasia
Adverse effect
Antibody
Bevacizumab
Bioinformatics
Biology
CD8
Chemokine
Chemotherapy
Clinical trial
Coronavirus disease 2019 (COVID-19)
Cytokine
Immunity
Infectious disease (medical specialty)
Lymphocyte
Mechanical ventilation
Mucocutaneous zone
Pathology
Pneumonia
Retrospective cohort study
Surgery
Telangiectases
Tumor necrosis factor alpha